Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
2.
Orv Hetil ; 142(37): 2021-3, 2001 Sep 16.
Article in Hungarian | MEDLINE | ID: mdl-11582733

ABSTRACT

14 patients suffering from early stage mycosis fungoides were treated with interferon alpha 2-a and PUVA/1 patient in stage I a, 3 patients in stage I b, 4 patients in stage II a and 6 patients in stage II b/during 3-21 months time course. Interferon alpha 2-a was administered 3 times a week, in escalating dose from 3 MU to 9 MU, determining the individual maximal tolerated dose. All of the patients responded well to the treatment. Partial remission was observed after 4-13 weeks of treatment. Total remission developed in 8 cases, after 8 weeks- 9 months of the treatment. Side effects occurred frequently: weight loss, pain, fever, fatigue, leucopenia, thrombopenia, liver enzyme elevation. Because of the side effects the dose of the interferon was reduced individually, the dose reduction did not cause relapse.


Subject(s)
Antineoplastic Agents/therapeutic use , Immunologic Factors/therapeutic use , Interferon-alpha/therapeutic use , Mycosis Fungoides/drug therapy , PUVA Therapy , Skin Neoplasms/drug therapy , Aged , Antineoplastic Agents/adverse effects , Female , Humans , Immunologic Factors/adverse effects , Interferon-alpha/adverse effects , Male , Middle Aged , Mycosis Fungoides/pathology , Neoplasm Staging , Skin Neoplasms/pathology , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...